The Future of GVHD Treatment
The panel shares new therapies for the treatment of chronic graft-versus-host disease they look forward to seeing in the future.
Tapering Approaches for Patients With Steroid-Refractory Chronic GVHD
Catherine Lee, MD, MS, details her approaches to tapering steroids in a refractory patient with chronic graft-versus-host disease and the efficacy of different treatments based on organ involvement.
Clinical Scenario: A 52-Year-Old Woman With Chronic GVHD
Nelson Chao, MD, MBA, presents the clinical scenario of a 52-year-old woman with chronic graft-versus-host disease for discussion.
Second-Line Treatment Options for Steroid-Refractory Chronic GVHD
Experts discuss the second-line treatment options for chronic graft-vs-host disease when steroids fail, including ruxolitinib.
Monitoring Patients Receiving Steroids for Chronic GVHD
Erin Kopp, NP, emphasizes the importance of identifying patient response to steroids, establishing steroid dependence, and using a systematic tapering regimen for effective management of chronic graft-vs-host disease.
Frontline Treatment Options for Chronic GVHD
The panel reviews treatment approaches for graft-versus-host disease when steroids are not an option and explains how the heterogeneity of GVHD makes finding the right treatment challenging.
Importance of Early Diagnosis and Treatment of GVHD
Key opinion leaders highlight the variable symptoms of chronic graft-versus-host disease and the importance of educating patients and community physicians to recognize and address early signs.
Assessing Symptoms of Chronic GVHD in Patients
Experts discuss the challenges of grading chronic graft-versus-host disease using NIH criteria, noting the importance of a common language, and considering patient symptoms, performance status, and organ involvement in assessing severity.
Clinical Scenario: A 53-Year-Old Man With Chronic GVHD
Nelson Chao, MD, MBA, presents the clinical scenario of a 53-year-old man with chronic graft-versus-host disease and highlights the complexities of distinguishing between symptoms of acute and chronic GVHD.
Key Takeaways from Two Post Hoc Analyses of the REACH2 Trial
Nelson J. Chao, MD, MBA, and Michael Grunwald, MD draw conclusions from two post hoc analyses of the REACH2 trial and share clinical pearls for community clinicians treating patients with acute Graft-Versus-Host Disease.
Post Hoc Analysis Review: REACH2 and Early vs. Late Treatment with Ruxolitinib
Panelists engage with a post hoc analysis of the REACH2 trial comparing early versus late treatment with ruxolitinib in patients with steroid-refractory acute Graft-Versus-Host Disease.
REACH 2 Post Hoc Analysis Review: and The Impact of Cytopenias on Patient Outcomes
Two subject matter experts discuss a post hoc analysis of the REACH2 trial, focusing on the impact of cytopenias on treatment outcomes in patients with steroid-refractory acute Graft-Versus-Host Disease.
Standard Treatments for Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
Drs Chao and Grunwald review available treatment options as informed by NCCN guidelines for patients with steroid-refractory acute Graft-Versus-Host Disease.
Understanding Acute Graft-Versus-Host Disease
Nelson J. Chao, MD, MBA, and Michael Grunwald, MD introduce acute Graft-Versus-Host Disease (GvHD), sharing how it is diagnosed, how it differs from chronic GvHD, and common signs and symptoms.
Future Directions in Graft vs Host Disease Management
Closing out their panel on GVHD management, expert hematologist/oncologists share their hope for future evolution in the treatment landscape.
Treatment Armamentarium for Chronic Graft vs Host Disease
Comprehensive discussion on the pharmacologic treatment armamentarium available for patients with chronic graft vs host disease.
Optimal Staging Strategies for Chronic Graft vs Host Disease
Expert hematologist/oncologists highlight challenges in staging chronic graft vs host disease and share strategies to optimize cGHVD assessment.
Scenario 2: A 59-Year-Old Woman With Chronic GVHD
After reviewing a clinical scenario of chronic graft vs host disease, panelists consider the importance of different allogeneic transplant types.
Selecting Therapy for Patients With a Partial Response to Frontline Therapy
Shared insight on treatment approaches toward patients with acute graft vs host disease who experience partial response to frontline therapy.
Selecting Optimal Therapy for Acute GVHD
Focusing on pharmacologic options, expert panelists review frontline treatment strategies for patients with acute graft vs host disease.
Biomarkers for the Prognostication of Graft vs Host Disease
Expert hematologist/oncologists share their perspectives on use of biomarkers to help prognosticate graft vs host disease.
Scenario 1: A 44-Year-Old Man With Acute Graft vs Host Disease
Centering discussion on a scenario of acute graft vs host disease, expert panelists consider optimal workup of a patient showing signs of GVHD.
Understanding the Pathophysiology of Acute vs Chronic GVHD
Shared insight on the pathophysiology of graft vs host disease, with specific regard for differences between acute GVHD vs chronic GVHD.
Armamentarium for Graft vs Host Disease Prophylaxis
Hematologist/oncologists provide a broad overview of the pharmacologic agents used to prevent graft vs host disease at their institutions.
GVHD in the Context of Stem Cell or Allogeneic Transplant
Expert panelists elucidate the occurrence of graft vs host disease in patients receiving either stem cell or allogeneic transplantation.
2 Commerce Drive Cranbury, NJ 08512